The EU Commission has adopted a recommendation for Member States to expedite the rollout of an age verification app to ensure safe online access for minors. The app is expected to be available by the end of 2026, addressing compliance with the Digital Services Act.
Why it matters. Failure to implement these measures could lead to increased scrutiny and penalties for platforms like Meta, which has already faced breaches of the Digital Services Act.
Our readExpect Member States to act quickly to avoid compliance issues; the clock is ticking.
Source · EU Digital Strategy
AlgorithmWatch has outlined recommendations for incorporating a ban on deepfakes into the EU's AI Act as part of the ongoing AI Omnibus procedure. This proposal aims to hold AI companies accountable for digital sexualized violence, addressing a critical gap in current regulations.
Why it matters. The proposed ban could reshape compliance strategies for tech firms deploying AI-driven content moderation tools.
Our readSignal: AI companies must prepare for stricter regulations on harmful content — compliance is non-negotiable.
Source · Algorithm Watch
The European Commission has preliminarily found that Meta's Instagram and Facebook platforms failed to prevent minors under 13 from accessing their services, potentially breaching the Digital Services Act. This finding could lead to significant penalties if confirmed.
Why it matters. Meta may face enforcement actions, including fines, if it does not address these compliance failures by the end of 2026.
Our readMeta's compliance strategies will be under intense scrutiny; expect potential repercussions soon.
Source · EU Digital Strategy
The National Institutes of Health has submitted a request to the Office of Management and Budget for public comments on the impact of clinical research training on healthcare professionals. This initiative aims to enhance the training framework and ensure informed practices in clinical settings.
Why it matters. Feedback will shape NIH's training programs, directly affecting compliance standards for clinical research institutions.
Our readWatch for updates on NIH's training initiatives; they will influence best practices in clinical research compliance.
Source · Federal Register
The FDA is proposing to withdraw approval for ChemoCentryx's TAVNEOS (avacopan) 10 mg capsules, citing safety concerns. The company has the opportunity to request a hearing to contest this decision, which could impact its market position significantly.
Why it matters. If finalized, this withdrawal could lead to a substantial revenue loss for ChemoCentryx, affecting investor confidence.
Our readChemoCentryx must act swiftly to defend its product; the stakes are high for its market reputation.
Source · Federal Register